Abstracts tagged "rheumatoid arthritis (RA) and treatment"

Abstract Number: 1327 • 2012 ACR/ARHP Annual Meeting
Comparison of Four Different Intensive Treatment Strategies in Patients with Early Rheumatoid Arthritis in Korea
Mi-Il Kang, Yoon Kang, Hee-Jin Park, Hyang-Sun Lee, Sang-Won Lee, Yong-Beom Park and Soo-Kon Lee, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
Background/Purpose: The previous studies reported that intensive treatment-strategies, including biological agents and glucocorticoids, can improve the severity of early rheumatoid arthritis. However, there was no…
Abstract Number: 1307 • 2012 ACR/ARHP Annual Meeting
Anti-IL-6 Receptor Nanobody (ALX-0061) Seamless “First-in-Human” Phase I/II POC Study in Patients with Active RA On Stable MTX Treatment
Steven De Bruyn¹, Béla Gachályi², Bernadette Rojkovich³, Slavomir Bruk⁴, Petr Sramek⁵, Mariusz Korkosz⁶, Krzysztof Krause⁷, Pieter Schoen⁸, Laura Sargentini-Maier⁹, Joke D'Artois¹⁰, Katrien Verschueren¹⁰, Katelijne De Swert¹⁰, Gerhard Arold¹¹ and Josefin-Beate Holz¹², ¹Clinical Development, Ablynx N.V., Zwijnaarde, Belgium, ²Fázis I-es Klinikai Farmakológiai Vizsgálóhely, Péterfy Sándor Utcai Kórház, Budapest, Hungary, ³II. sz. Reumatológiai Osztály, Budai Irgalmasrendi Kórház Kht., Budapest, Hungary, ⁴Interni oddeleni, Nemocnice Trinec, Trinec, Czech Republic, ⁵Pharmaceutical Research Associates CZ, Praha, Czech Republic, ⁶Malopolskie Centrum Medyczne, Krakow, Poland, ⁷Specjalistyczny im. J. Gromkowskiego, Wojewodzki Szpital, Wroclaw, Poland, ⁸Project Management, Ablynx N.V., Zwijnaarde, Belgium, ⁹Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, ¹⁰Clinical Development, Ablynx nv, Zwijnaarde, Belgium, ¹¹Medical Affairs, PRA International GmbH, Berlin, Germany, ¹²Chief Medical Officer, Ablynx N.V., Zwijnaarde, Belgium
Background/Purpose: ALX-0061 is a 26kD bispecific IL-6R targeting Nanobody® with monovalent binding to IL-6R and serum albumin. It effectively neutralizes IL-6 pathway activity in-vitro and…
Abstract Number: 983 • 2012 ACR/ARHP Annual Meeting
Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 As a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis
Jing Cui¹ and International RA Consortium on Therapy (InteRACT)², ¹Rheumatology, Brigham and Women's Hospital, Boston, MA, ²Division of Rheumatology, Immunology and Allergy and Division of Genetics, Boston, MA
Background/Purpose: There are no biomarkers that predict response to anti-TNF therapy in rheumatoid arthritis (RA). Here, we conduct a genome-wide association study (GWAS) to identify…
Abstract Number: 833 • 2012 ACR/ARHP Annual Meeting
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Multiple-Dose Study of Intravenous Staphylococcal Protein A in Patients with Active Rheumatoid Arthritis On Methotrexate: Safety, Pharmacokinetics and Efficacy
Edward Bernton¹, Eduard Krantz² and William Gannon Jr.³, ¹Protalex Inc., Summit, NJ, ²Parexel Clinical Pharmacology, Bloemfontein, South Africa, ³Capital City Technical Consulting, Inc., Washington, DC
Background/Purpose: PRTX-100 is highly-purified GMP staphylococcal protein A (SpA) that binds with extremely high affinity to the Vh antibody framework region of Clade Vh3 immunoglobulins. …
Abstract Number: 497 • 2012 ACR/ARHP Annual Meeting
Golimumab Drug Utilization Patterns in Canada – Higher Retention Rate in Golimumab Treated Rheumatoid Arthritis Patients Compared to Etanercept and Adalimumab
Hayssam Khalil¹ and Amir Tahami², ¹Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada, ²Janssen Canada Inc., Toronto, ON, Canada
Background/Purpose: Golimumab is a monthly self-injected anti-tumor necrosis factor alpha therapy for patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA). It…
Abstract Number: 499 • 2012 ACR/ARHP Annual Meeting
What Is the Right Dose to Start Methotrexate (7.5 or 15mg) in Rheumatoid Arthritis? (A Randomized Controlled Trial)
Varun Dhir¹, Mandeep Singla², Palvi Goyal², Vinay Sagar², Aman Sharma¹ and Shefali K. Sharma², ¹Internal Medicine (Rheumatology Unit), Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²Internal Medicine (Rheumatology Unit), Post Graduate Institute of Medical Education and Research, Chandigarh, India
Background/Purpose: Recent recommendations have suggested higher starting doses of methotrexate, i.e. 15 mg/week (3E initiative) in rheumatoid arthritis. However, studies comparing conventional (7.5mg) and newer…
Abstract Number: 372 • 2012 ACR/ARHP Annual Meeting
TRAF1/C5 Locus Is Associated with Response to Anti-Tumor Necrosis Factor Therapy in Patients with Rheumatoid Arthritis
Helena Canhao¹, Ana M. Rodrigues², Maria José Santos³, Diana Carmona-Fernandes⁴, Bruno Bettencourt⁵, Jing Cui⁶, Fabiana Rocha⁵, Jose canas Silva³, Joaquim Polido Pereira⁷, Jose Alberto Pereira Silva⁸, José Antonio Costa⁹, Domingos Araujo¹⁰, Candida Silva¹¹, Helena Santos¹², Catia Duarte¹³, Fernando Pimentel-Santos¹⁴, Jaime C. Branco¹⁴, Robert M. Plenge¹⁵, Daniel H. Solomon¹⁶, Jacome Bruges Armas⁵, José A. P. Da Silva¹⁷, João E. Fonseca¹⁸ and Elizabeth W. Karlson¹⁹, ¹Rheumatology Research Unit, Rheumatology Research Unit, on behalf of the Rheumatic Diseases Portuguese Register, Instituto de Medicina Molecular, Rheumatology Research Unit, Rheumatology Research Unit, on behalf of the Rheumatic Diseases Portuguese Register, Lisbon, Portugal, ²2- Rheumatology Research Unit,, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Lisbon, Portugal, ³Rheumatology Department, Hospital Garcia de Orta, E.P.E., Almada, Portugal, ⁴Rheumatology Research Unit Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Lisbon, Portugal, ⁵Seebmo, Hospital de Santo Espirito da Ilha Terceira, Ilha Terceira, Portugal, ⁶Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁷Rheumatology Research Unit, Instituto Medicina Molecular, Lisbon, Portugal, ⁸Rheumatology Department, Santa Maria Hospital, Lisbon, Portugal, ⁹Rheumatology, Centro Hospitalar do Alto Minho, Hospital de Ponte de Lima, Ponte de Lima, Portugal, ¹⁰Rheumatology Department, Unidade Local de Saude, Ponte de Lima, Portugal, ¹¹Reumatology, Instituto Portugues Reumatologia, Lisbon, Portugal, ¹²Rheumatology, Instituto Português de Reumatologia, Lisboa, Portugal, ¹³Rheumatology, Hospitais da Universidade de Coimbra, Coimbra, Portugal, ¹⁴Rheumatology, Centro Hospitalar de Lisboa Ocidental, Hospital Egas Moniz, Lisboa, Portugal, ¹⁵Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ¹⁶Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, ¹⁷Serviço de Reumatologia, Centro Hospitalar e Universitário de Coimbra – Hospitais da Universidade de Coimbra, E.P.E., Coimbra, Portugal, ¹⁸Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa and Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, Lisboa, Portugal, ¹⁹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Some of the allelic variants associated with rheumatoid arthritis (RA) susceptibility are related to tumor necrosis factor (TNF) signaling pathways. We hypothesized that they…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.